We advised Amneal Pharmaceuticals on its high-yield notes offering

Davis Polk advised Amneal Pharmaceuticals, Inc. in connection with a Rule 144A / Regulation S offering of $600 million aggregate principal amount of its 6.875% senior secured notes due 2032 issued by its indirectly wholly owned subsidiary Amneal Pharmaceuticals LLC. The proceeds, together with the proceeds of new terms loans, will be used to repay the company’s existing term loans, to repay outstanding amounts under the company’s ABL facility and for general corporate purposes.

Amneal Pharmaceuticals, headquartered in Bridgewater, New Jersey, is a global biopharmaceutical company. Amneal Pharmaceuticals makes healthy possible through the development, manufacturing and distribution of a diverse portfolio of over 280 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, Amneal Pharmaceuticals is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal Pharmaceuticals has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, Amneal Pharmaceuticals is a distributor of pharmaceuticals and other products for the U.S. federal government, retail and institutional markets.

The Davis Polk capital markets team included partners Michael Kaplan and Stephen A. Byeff, counsel Claudia Carvajal Lopez and associates Cheridan Christnacht and Kristiana J. Olson. The sponsor finance team included partner Jack Orford, counsel Yuko Sin and associate Zachariah C. Taylor. Partner Lucy W. Farr and counsel Leslie J. Altus provided tax advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post